Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Tularik Inc. (NasdaqNM:TLRK)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
July 25Conference call: Tularik Earnings (Q2 2001)
Location
Two Corporate Drive South
South San Francisco, CA 94080
Phone: (650) 825-7000
Fax: (650) 825-7303
Employees (last reported count): 279
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 61%
·Over the last 6 months:
 · 4 insider sells; 43.0K shares
  (0.1% of insider shares)
·Institutional: 28% (70% of float)
(155 institutions)
·Net Inst. Buying: 2.16M shares (+13.74%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Tularik Inc. is engaged in the discovery and development of a broad range of orally available drugs based on gene regulation. The Company's research programs, all of which address attractive commercial markets, include cancer, cytomegalovirus, diabetes, obesity, inflammation, allergy/asthma, lipid disorders, bacterial diseases and a class of drug targets called orphan nuclear receptors. Tularik has diversified its drug discovery and development efforts not only across a large number of diseases, but also across multiple promising targets and drug candidates for these diseases.
More from Market Guide: Expanded Business Description

Financial Summary
Tularik Inc., engages in the discovery and development of a broadrange of novel orally available drugs based on gene regulation. For the six months ended 6/30/01, revenues rose 34% to $15.4 million. Net loss before acctg. change fell 6% to $21.1 million. Revenues reflect collaborative research payments from Japan Tabacco and Knoll AG. Lower loss was partially offset by an increased number of clinical and preclinical studies and increased headcount.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

A. Heidrich III, 47
Chairman
--  --  
David Goeddel, Ph.D., 48
CEO
$351K$1.3M
Andrew Perlman, M.D., Ph.D., 52
Exec. VP
252K319K
Corinne Lyle, 39
VP, CFO
--  --  
William Rieflin, 39
VP, Gen. Counsel and Sec.
259K--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:TLRKAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$16.125
Recent Price$23.10 
52-Week High
on 25-Sep-2000
$36.688
Daily Volume (3-month avg)133.8K
Daily Volume (10-day avg)125.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-30.9%
52-Week Change
relative to S&P500
-7.3%
Share-Related Items
Market Capitalization$1.14B
Shares Outstanding49.2M
Float19.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.65 
Earnings (ttm)-$0.77 
Earnings (mrq)-$0.24 
Sales (ttm)$0.61 
Cash (mrq)$4.60 
Valuation Ratios
Price/Book (mrq)4.96 
Price/EarningsN/A 
Price/Sales (ttm)37.91 
Income Statements
Sales (ttm)$29.3M
EBITDA (ttm)-$49.5M
Income available to common (ttm)-$37.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-11.87%
Return on Equity (ttm)-15.09%
Financial Strength
Current Ratio (mrq)5.77 
Debt/Equity (mrq)0.07 
Total Cash (mrq)$226.0M
Short Interest
As of 8-Aug-2001
Shares Short838.0K
Percent of Float4.4%
Shares Short
(Prior Month)
798.0K
Short Ratio7.29 
Daily Volume115.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.